# Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07229339/  
OnCo record `nct07229339` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of carboplatin, pemetrexed and zipalertinib in lung cancer, run by Jonsson Comprehensive Cancer Center, not yet recruiting.

## Summary

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07229339 by Jonsson Comprehensive Cancer Center, with a registry enrolment figure of 16 participants, started 2027-06-01 and due to reach its primary completion in 2029-06-01. Interventions recorded: Biospecimen Collection; Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Pemetrexed; Positron Emission Tomography; Zipalertinib. Conditions listed: Lung Non-Squamous Non-Small Cell Carcinoma. Primary outcome: Major pathologic response. Lung eligibility wording from the registry: "* Histologically confirmed non-squamous NSCLC performed within 90 days of enrollment with EGFR Ex20Ins-mutated (addition of 1 or more amino acids) or uncommon/compound EGFR mutations (E709X, G719X, L747X, S758I, and/or L861Q) in tumor tissue or blood; any one of these mutations would qualify if comp". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07229339
- Phase: 2
- Setting: Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations
- Sponsor: Jonsson Comprehensive Cancer Center
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT07229339: https://clinicaltrials.gov/study/NCT07229339

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Zipalertinib](https://onco.cc/drugs/zipalertinib/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07229339.json